Drug Stock Reaches New Highs on Growth-Hormone Win

ASND stock is pacing for its best day ever

Digital Content Manager
Mar 4, 2019 at 9:52 AM
facebook twitter linkedin


The shares of Ascendis Pharma (NASDAQ:ASND) are up 66% at $114.96 this morning, after the company's pediatric growth-hormone drug, TransCon, succeeded in meeting the main goal of a late-stage trial. The win has ASND trading at record highs, and pacing for its best day ever.

Prior to today's rally, the stock was up 10.6% year-to-date, and was struggling to surmount the $75-$77 area -- home to its previous all-time highs. Now, ASND is traveling well above its old highs, peaking at $115.50 in early trading. 

Analysts have shown resounding optimism for Ascendis of late, with all eight giving it a "strong buy" rating. However, there could be some price-target hikes in the cards, as the consensus 12-month target price of $85.78 now represents a steep discount to the stock's current perch. 

Meanwhile, plenty of short sellers could be kicking rocks today. Short interest rose 27.3% in the most recent reporting period. At ASND's average daily trading volume, it would take almost a week for bears to cover these pessimistic positions -- hinting at potential tailwinds in the form of a short squeeze. 

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners